Point72 Asset Management
XENE icon

Point72 Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Point72 Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-209,759
Closed -$7.04M – 2658
2025
Q1 		$7.04M Buy
+209,759
New +$7.96M 0.02% 807
2024
Q4 		– Sell
-383,290
Closed -$15.1M – 2514
2024
Q3 		$15.1M Sell
383,290
-98,732
-20% -$3.98M 0.04% 507
2024
Q2 		$18.8M Buy
482,022
+206,163
+75% +$8.24M 0.05% 414
2024
Q1 		$11.9M Sell
275,859
-599,206
-68% -$27.6M 0.03% 652
2023
Q4 		$40.3M Sell
875,065
-250,643
-22% -$8.86M 0.1% 261
2023
Q3 		$38.5M Buy
1,125,708
+977,500
+660% +$36.6M 0.11% 229
2023
Q2 		$5.71M Sell
148,208
-356,416
-71% -$14.2M 0.02% 773
2023
Q1 		$18.1M Sell
504,624
-673,700
-57% -$24.9M 0.06% 385
2022
Q4 		$46.5M Sell
1,178,324
-461,748
-28% -$16.8M 0.16% 165
2022
Q3 		$59.2M Buy
1,640,072
+738,566
+82% +$26.6M 0.24% 106
2022
Q2 		$27.4M Sell
901,506
-1,244,944
-58% -$37.7M 0.12% 238
2022
Q1 		$65.6M Sell
2,146,450
-846,147
-28% -$25.3M 0.26% 101
2021
Q4 		$93.5M Buy
2,992,597
+1,914,797
+178% +$57.2M 0.37% 49
2021
Q3 		$16.5M Buy
1,077,800
+175,500
+19% +$3.05M 0.07% 362
2021
Q2 		$16.8M Buy
902,300
+141,299
+19% +$2.6M 0.08% 327
2021
Q1 		$13.6M Buy
761,001
+288,022
+61% +$4.88M 0.06% 352
2020
Q4 		$7.27M Buy
472,979
+25,918
+6% +$303K 0.04% 515
2020
Q3 		$4.95M Sell
447,061
-212,343
-32% -$2.5M 0.03% 566
2020
Q2 		$8.27M Buy
659,404
+74,351
+13% +$946K 0.05% 380
2020
Q1 		$6.63M Sell
585,053
-270,747
-32% -$3.86M 0.05% 352
2019
Q4 		$11.2M Sell
855,800
-69,200
-7% -$728K 0.06% 361
2019
Q3 		$8.33M Hold
925,000
– – 0.05% 383
2019
Q2 		$9.12M Buy
925,000
+75,000
+9% +$718K 0.05% 400
2019
Q1 		$8.64M Buy
850,000
+125,000
+17% +$1.06M 0.04% 436
2018
Q4 		$4.58M Buy
725,000
+325,000
+81% +$2.89M 0.02% 576
2018
Q3 		$5.28M Buy
400,000
+321,900
+412% +$3.73M 0.02% 583
2018
Q2 		$719K Sell
78,100
-228,979
-75% -$1.42M ﹤0.01% 858
2018
Q1 		$1.5M Sell
307,079
-3,100
-1% -$11.5K 0.01% 771
2017
Q4 		$876K Hold
310,179
– – ﹤0.01% 813
2017
Q3 		$915K Hold
310,179
– – ﹤0.01% 753
2017
Q2 		$977K Hold
310,179
– – 0.01% 732
2017
Q1 		$1.24M Hold
310,179
– – 0.01% 714
2016
Q4 		$2.39M Sell
310,179
-48,352
-13% -$388K 0.02% 544
2016
Q3 		$2.9M Hold
358,531
– – 0.02% 515
2016
Q2 		$2.12M Hold
358,531
– – 0.01% 553
2016
Q1 		$2.51M Buy
358,531
+41,146
+13% +$296K 0.02% 538
2015
Q4 		$2.55M Hold
317,385
– – 0.02% 515
2015
Q3 		$2.62M Buy
317,385
+50,045
+19% +$497K 0.02% 526
2015
Q2 		$3.08M Buy
267,340
+157,340
+143% +$2.18M 0.02% 529
2015
Q1 		$1.85M Buy
+110,000
New +$2.03M 0.01% 566

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Point72 Asset Management's XENE Position: Q2 2025 in Review

Point72 Asset Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 209,759 shares — an estimated $7.04M sold.

Point72 Asset Management first reported a position in XENE in Q1 2015 and held it in 40 quarters. The position peaked at $93.5M in Q4 2021. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Point72 Asset Management reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Point72 Asset Management sold 209,759 Xenon Pharmaceuticals shares in Q2 2025, an estimated $7.04M.
  • Point72 Asset Management first reported a position in Xenon Pharmaceuticals in Q1 2015 and held it in 40 quarters.
  • Point72 Asset Management's Xenon Pharmaceuticals position peaked at $93.5M in Q4 2021.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Point72 Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.